DAT

About TheraCryf

TheraCryf is a clinical-stage biotech developing innovative small molecule therapies for high-unmet-need brain disorders, with a strategy centered on proof-of-concept development followed by partnership with larger pharma. Its pipeline includes two advanced preclinical assets: a 'best-in-class' orexin-1 antagonist (Ox-1) for addictive behaviors and anxiety, and an atypical dopamine transporter inhibitor (DAT) for fatigue and narcolepsy. A third asset, SFX-01 (a stabilized sulforaphane), is being explored in glioblastoma via an external collaboration. The company is pre-revenue and aims to advance its lead program to clinic readiness by 2026.

Therapeutic Areas